The theory that IL-6/IL-10 is a good prognostic marker for use in clinical practice was based on the following reasons: i) high levels of IL-10, with consequent decrease in IL-6/IL-10, indicate tumour immunosuppression, eliminating the ability of immunocompetent cells to respond to the tumour (26); ii) IL-10 is known to be a promoter of immune dysregulation, with the enhancement of Th2 cells (27). This evidence concerns the gene IL6 and neoplasm.